Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Angler - Who is the Brad that you continually speak of ?

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jul 20, 2023 8:48am

175 Views

Post# 35549441

RE:RE:RE:RE:RE:RE:RE:Angler - Who is the Brad that you continually speak of ?

The longer this process takes the more the SP will decline on zero news. I take some solace in Coffey's 90 day statement, but not a lot...remember ASCO brought very little. If the goal was to get the SP up towards $20 before a deal, well, they have work to do.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario